Timing Exercise Training as Strategy to Improve Insulin Sensitivity and Substrate Metabolism in Men and Woman With Pre-diabetes (Timed Training)

August 23, 2023 updated by: Maastricht University Medical Center

n a retrospective analysis of an exercise training program performed either in the morning or afternoon, we found that the afternoon training group improved their peripheral insulin sensitivity and fasting plasma glucose levels to a greater extent than the morning group. However, underlying mechanisms are unclear.

The main objective of this study is to determine whether prolonged exercise training in the afternoon (15:00-17:00 PM) differs from exercise training in the morning (07:00-09:00 AM) in improving insulin sensitivity in individuals with pre-diabetes, and to investigate its underlying mechanisms.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Rationale: Various metabolic processes, including resting metabolic rate, insulin sensitivity and insulin secretion, follow a recurring 24-hour cycle. These rhythms are shown to be disturbed in in pre-diabetes volunteers compared to young healthy volunteers. In a retrospective analysis of an exercise training program performed either in the morning or afternoon, we found that the afternoon training group improved their peripheral insulin sensitivity and fasting plasma glucose levels to a greater extent than the morning group. However, underlying mechanisms are unclear.

Objective: The main objective of this study is to determine whether prolonged exercise training in the afternoon (15:00-17:00 PM) differs from exercise training in the morning (07:00-09:00 AM) in improving insulin sensitivity in individuals with pre-diabetes, and to investigate its underlying mechanisms.

Study design: The present study is a randomized double arm longitudinal intervention study in a pre and post design.

Study population: 24 pre-diabetic individuals (men and postmenopausal women aged 40 - 75 years and with BMI ≥ 25 and ≤ 38 kg/m2) will complete this study (12 participants in the morning training group and 12 participants in the afternoon training group). From experience with similar studies, we estimate a drop-out rate of 20% and a screening failure of 70% (because individuals often do not know they are pre-diabetic). This results in maximally 30 participants that have to be included and 100 participants that have to be screened (maximally).

Intervention (if applicable): Participants will perform a 12-weeks supervised high intensity interval training (HIIT) program with three ~30 min exercise sessions per week. Participants will be randomly assigned to the morning or afternoon training time. To assess the outcomes, participants will come to the university for a 43h measurement period both before and after the 12-week training program.

Main study parameters/endpoints: The primary study endpoint is peripheral insulin sensitivity measured via a 2-step hyperinsulinemic-euglycemic clamp. The secondary outcomes are 24h energy and substrate metabolism. Exploratory outcomes are body composition, intrahepatic lipid content and composition, hepatic insulin sensitivity, hepatic glycogen levels, maximal aerobic capacity, skeletal muscle oxidative capacity, visceral and subcutaneous adipose tissue volume, sleeping metabolic rate, blood glucose levels (continuously measured over 7days) and immune responses.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 40-75 years.
  • Body mass index (BMI) ≥25 kg/m2
  • Male, or postmenopausal (at least 1 year post cessation of menses) female
  • Pre-diabetes based on one or a combination of the following criteria:

    • Impaired Glucose Tolerance (IGT): plasma glucose values ≥ 7.8 mmol/l and ≤ 11.1 mmol/l 120 minutes after glucose drink consumption during OGTT in screening
    • ImpairedFastingGlucose(IFG):Fastingplasmaglucose≥6.1mmol/land≤6.9 mmol/l
    • Insulin Resistance: glucose clearance rate ≤ 360 mL/kg/min, as determined during the OGTT using OGIS120.
    • HbA1cof5.7-6.4%

Exclusion Criteria:

  • Type 2 diabetes
  • Patients with active congestive heart failure and and/or severe renal and or liver insufficiency
  • Uncontrolled hypertension
  • Any contra-indication for MRI scanning
  • Alcohol consumption of >3 servings per day for man and >2 servings per day for woman
  • Smoking
  • Unstable body weight (weight gain or loss > 5kg in the last 3 months)
  • Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator which would possibly hamper our study results.
  • Medication use known to hamper subject's safety during the study procedures.
  • Subjects who do not want to be informed about unexpected medical findings.
  • Men: Hb <8.0 mmol/L, Women: Hb <7.0 mmol/l
  • Heavily varying sleep-wake rhythm (i.e. night shift work and travels across time zones).
  • Significant food allergies/intolerance (seriously hampering study meals)
  • Blood donation during or within 2 months prior to the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AM exercise
HIIT program performed between 07:00-09:00 AM
High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
Experimental: PM exercise
HIIT program performed between 15:00-17:00 PM
High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peripheral Insulin sensitivity
Time Frame: measured before and after the 12 weeks training program
Glucose disposal rate under high insulin concentrations during the second step of the 2-step hyperinsulinemic-euglycemic clamp.
measured before and after the 12 weeks training program

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
24h whole body energy expenditure
Time Frame: measured before and after the 12 weeks training program
energy expenditure as measured by a 24h stay in the respiration chamber
measured before and after the 12 weeks training program
24h substrate metabolism
Time Frame: measured before and after the 12 weeks training program
24h substrate metabolism as measured by a 24h stay in the respiration chamber
measured before and after the 12 weeks training program

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body composition by Dual Energy X-ray Absorptiometry (DEXA)
Time Frame: measured before and after the 12 weeks training program
fat-free mass (kg and percentage)
measured before and after the 12 weeks training program
Body composition by Dual Energy X-ray Absorptiometry (DEXA)
Time Frame: measured before and after the 12 weeks training program
fat mass (kg and percentage)
measured before and after the 12 weeks training program
Intrahepatic lipid content and composition
Time Frame: measured before and after the 12 weeks training program
measured before and after the 12 weeks training program
Hepatic glycogen levels
Time Frame: measured before and after the 12 weeks training program
measured before and after the 12 weeks training program
VO2 max cycling test
Time Frame: measured before and after the 12 weeks training program
measurement of participants' maximal aerobic capacity, absolute (L/min) and relative (ml/min/kg)
measured before and after the 12 weeks training program
Skeletal muscle oxidative capacity
Time Frame: measured before and after the 12 weeks training program
Ex vivo high-resolution respirometry using a two chamber Oxygraph (OROBOROS Instruments) will be performed. Multiple substrate/inhibitor titration protocols will be applied to extensively characterize the mitochondrial capacity of skeletal muscle fibers
measured before and after the 12 weeks training program
Sleeping metabolic rate
Time Frame: measured before and after the 12 weeks training program
measured before and after the 12 weeks training program
Blood glucose levels measured continuously over 7 days.
Time Frame: measured before and at the end the 12 weeks training program
measured before and at the end the 12 weeks training program

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 13, 2023

Primary Completion (Estimated)

March 1, 2026

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

July 20, 2023

First Submitted That Met QC Criteria

August 23, 2023

First Posted (Actual)

August 28, 2023

Study Record Updates

Last Update Posted (Actual)

August 28, 2023

Last Update Submitted That Met QC Criteria

August 23, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight and Obesity

Clinical Trials on Timing of exercise

3
Subscribe